First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset

This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death ligand 1 (PD‐L1) tumor proportion score of 50% or higher e...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Satouchi, Miyako, Nosaki, Kaname, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Aoe, Keisuke, Kurata, Takayasu, Sekine, Akimasa, Horiike, Atsushi, Fukuhara, Tatsuro, Sugawara, Shunichi, Umemura, Shigeki, Saka, Hideo, Okamoto, Isamu, Yamamoto, Nobuyuki, Sakai, Hiroshi, Kishi, Kazuma, Katakami, Nobuyuki, Horinouchi, Hidehito, Hida, Toyoaki, Okamoto, Hiroaki, Atagi, Shinji, Ohira, Tatsuo, Han, Shi Rong, Noguchi, Kazuo, Ebiana, Victoria, Hotta, Katsuyuki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7734005/
https://ncbi.nlm.nih.gov/pubmed/32926507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14647
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia